Business Wire

MI-EATON

Share
Eaton’s Royal Power Solutions to display commercial vehicle terminals and connectors portfolio at IAA Transportation show

Power management company Eaton announced Royal Power Solutions (RPS), a leading provider of high-precision electrical connectivity components that it acquired earlier this year, is now providing its industry-leading components to commercial vehicle manufacturers. RPS components will be displayed Sept. 20-25 in Eaton’s exhibit at the IAA Transportation show in Hannover, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005003/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s Royal Power Solutions is an industry-leading provider of critical high-precision power- and signal-distribution terminals and connectors. (Photo: Business Wire)

RPS, established in 1938, is a global leader in the development and production of critical high-precision power- and signal-distribution terminals and connectors. Eaton is utilizing RPS products in its eMobility business and expanding its global market opportunities, including in Europe, Middle East and Africa (EMEA).

“Eaton’s global footprint and diversification have broadened Royal Power Solutions’ reach and ability to grow in EMEA,” said Tom Ross, president, Eaton’s Royal Power Solutions. “The market for terminals and connectors in EMEA continues to expand in parallel with electrification solutions, which are being increasingly adopted by our commercial vehicle customers.”

Electrified commercial vehicles need more power than traditional passenger vehicles to operate varying systems. RPS, recognized for its numerous industry-leading electrical solutions, provides terminals, connectors and other electrical components designed to handle current levels up to 500 amps. Among those components are stamped battery and eyelet terminals that can withstand vibration and harsh environments, making them ideal for commercial vehicles.

High Power Lock Box connectors provide protection, superior performance

Eaton’s RPS specialized High Power Lock Box (HPLB) power connectors are ideal for current electrified commercial vehicle solutions and can help reduce common warranty issues. The HPLB connectors offer superior performance, cost savings and reduced manufacturing complexity. They also provide efficiency and reliability and are strong enough to withstand high-pressure water spray.

HPLB terminals are a “plug-in” solution with a smaller footprint, resulting in less weight and a reduced profile compared to traditional terminals. Eaton’s RPS uses a progressive stamping process to manufacture the HPLB profiles rather than the more costly complex billet machining, stamping and forming process that competitive products require.

Unlike traditional male-to-female terminal connections, Eaton’s RPS HPLB terminals use a unique inverted contact system that provides improved contact force as the temperature increases, creating a stronger connection.

RPS busbars feature low profile, flexibility to meet design requirements

Another RPS component now available to Eaton’s EMEA commercial vehicle customers is RigiFlexTM busbars, manufactured in copper or aluminum based on customer requirements. With a unique, simple, single-piece flow manufacturing process, Eaton can scale volume to meet any customer specification.

The RigiFlex busbar is rigid in some areas but flexible in sections that require elevation changes within the system design. This flexibility also works well across the battery pack in areas that need tolerance for expansion and contraction due to fluctuating temperatures during charging and discharging cycles.

Eaton’s RPS busbars have a low profile to enable space-efficient design without heat sinks, which leads to weight savings. Eaton also can produce busbars with a level of flatness over length unmatched by competitors, which fulfills size and design requirements. Eaton’s RPS can leverage an automated assembly process to provide superior safety, reduce production time and offer maximum cost savings with little wasted material and nearly zero development time for production products.

Eyelet terminals sealed, protected against galvanic corrosion

Eaton’s eyelet terminals, another RPS solution, are crafted with sophisticated engineering and produced in our state-of-the-art stamping facilities. Sourcing eyelet terminals from RPS provides numerous benefits, including the ability to produce billions of parts annually for the single sourcing of large programs.

Traditionally, eyelet terminals in commercial vehicle electrical components are not sealed, exposing them to road spray and salt that accelerate galvanic corrosion. Eaton’s eyelet terminals from RPS provide fully sealed connectors that are resistant to severe vibration and deliver a component service life exceeding customer requirements.

“RPS has decades of design, manufacturing and stamping experience that is being leveraged in the introduction of new energy-transfer technologies,” Ross said. “Many of the components RPS supplies, including eyelets, busbars, High Power Lock Box terminals and full-service connectors, are essential in today’s commercial vehicles.”

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, operate sustainably, and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for its stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005003/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye